Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII)
- PMID: 19151125
- PMCID: PMC2818045
- DOI: 10.1177/0961203308098988
Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII)
References
-
- Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center, III. Improved survival over 24 years. J Rheumatol. 1997;24:1061–1065. - PubMed
-
- Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41:831–837. - PubMed
-
- Fernández M, Calvo-Alén J, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic U.S. cohort LUMINA XXI: Disease activity, damage accrual and vascular events in pre and postmenopausal women. Arthritis Rheum. 2005;52:1655–1664. - PubMed
-
- Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27:373–376. - PubMed
-
- Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–1118. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
